Related Experiment Video

Updated: Dec 18, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

11.8K

Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with

Masakazu Yamamoto1,2, Ikuko Suzuki2, Kouji Saitou3

  • 1Department of Neurology, Hematology, Metabolism, Endocrinology and Diabetology, Yamagata University School of Medicine, Yamagata, Japan.

Journal of Cancer Research and Clinical Oncology
|June 12, 2020
PubMed

Insights

Comorbidity and relative dose intensity (RDI) impact survival in diffuse large B-cell lymphoma (DLBCL). Maintaining RDI of at least 70% may improve outcomes, particularly for elderly DLBCL patients.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Research

Background:

  • Comorbidity and relative dose intensity (RDI) are known prognostic factors in diffuse large B-cell lymphoma (DLBCL).
  • The combined impact of comorbidity and RDI on DLBCL patient survival has not been fully elucidated.
  • Understanding these factors is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the independent and combined effects of comorbidity (using Charlson Comorbidity Index - CCI) and RDI on survival outcomes in DLBCL patients.
  • To determine if RDI influences survival independently of comorbidity, particularly in elderly DLBCL patients.

Main Methods:

  • Retrospective analysis of 211 consecutive DLBCL patients treated between January 2010 and October 2018.
  • Evaluation of clinical characteristics, Charlson Comorbidity Index (CCI), and relative dose intensity (RDI).
  • Statistical analysis, including multivariate analysis, to assess the impact of CCI and RDI on event-free survival (EFS) and overall survival (OS).

Main Results:

  • Higher comorbidity (CCI ≥ 2) and lower RDI (< 70%) were both associated with poorer EFS and OS.
  • Multivariate analysis indicated that RDI < 70% was an independent poor prognostic factor for OS in elderly DLBCL patients (age ≥ 65).
  • Elderly patients with both high comorbidity (CCI ≥ 2) and low RDI (< 70%) exhibited the worst OS and EFS compared to other groups.

Conclusions:

  • Charlson Comorbidity Index (CCI) ≥ 2 is associated with poorer outcomes in DLBCL patients.
  • Maintaining a relative dose intensity (RDI) of ≥ 70% may improve survival outcomes.
  • RDI is a significant independent prognostic factor for overall survival in elderly DLBCL patients, underscoring its importance in treatment management.
Abstract

Keywords:
ComorbidityDiffuse large B-cell lymphomaElderlyRelative dose intensity

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
320
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
124
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K